First Tracks (TRAX) CMO Paul F. Lizzul Receives 60,492 PSUs

What Happened
Paul F. Lizzul, Chief Medical Officer of First Tracks Biotherapeutics, was granted 60,492 performance-based restricted stock units (PSUs) on August 15, 2026. The award was reported as a derivative acquisition at an acquisition price of $0. Each PSU represents a conditional right to receive one share of the company’s common stock upon vesting; the award was certified by the Compensation Committee.

Key Details

• Transaction date: August 15, 2026; Form 4 filed August 18, 2026 (filing appears timely).
• Instrument and amount: 60,492 performance-based RSUs (PSUs) acquired at $0 (derivative grant).
• Vesting/settlement: 50% vests and settles on August 15, 2027; remaining 50% vests and settles on July 1, 2028, contingent on continued service and performance certification.
• Each PSU = right to one share upon vesting.
• Shares owned after transaction: Not specified in the provided filing.
• No sale or cash purchase occurred; this is a compensation grant, not a market trade.

Context
Performance-based RSUs are conditional awards that convert to actual shares only if performance goals and service requirements are met and the PSUs vest. Such awards are common as executive compensation and do not represent an immediate cash investment or sale by the insider.